Autologous bone graft

Yuan H, Fernandes H, Habibovic P, de Boer J, Barradas AM, de Ruiter A, et al. Osteoinductive ceramics as a synthetic alternative to autologous bone grafting. P Natl Acad Sci USA 2010 107 13614-9. 

Fonseca, R. J. Clark, P. J. Burkes, E. J. Baker, R. D. Revascularization and heahng of onlay particulate autologous bone grafts in primates. J. Oral Maxtllofac. Surg. 1980, 38, 572-577. 

Fig. 21.5 Two-staged surgery case with bone grafting of the tunnels. Twenty-seven years old female. Preoperative CT images (a) axial view and (b) sagittal view. Postoperative CT images (after autologous bone grafting) (c) axial view and (d) sagittal view...

Keating, J. F. and Mcqueen, M. M. 2001. Substitutes for autologous bone graft in orthopaedic trauma. Journal of Bone and Joint Surgery-British Volume, 83B, 3-8. 

Welch, R.D., Zhang, H., and Bronson, D.G. (2003). Experimental tibial plateau fractures augmented with calcium phosphate cement or autologous bone graft. J. Bone Joint Surg. Am. 85 222-31. 

In eastern Europe. Letoozim , a mixture of the papaya proteinases, is used for the treatment of eye burns [115] as well as for some cases of cataract [1161. Recently, a new application for chymopapain has been reported, Chymodiactin has been used in the process of removal of tumor cells from autologous marrow grafts in a positive selection system [117,118], This process clears the way for the use of autologous bone marrow transplants in the treatment of several types of cancer, since the authors showed tlst hemopoietic stem cells, the nrecyr ors of al lymphohemopoietic lineages, are present in cell mixtures purified in this way [119],... 

An unusually high incidence of skin eiythema (70-85%) was noted in patients who received aldesleukin after autologous bone marrow transplantation. Histological examination showed features of cutaneous graft-versus-host disease or T cell epidermal infiltrates, but cutaneous toxicity was not reproduced in patients receiving low-dose aldesleukin (100,101). 

Costello R, Blaise D, Jacquemier J, Monges G, Stoppa AM, Viens P, Olive D, BouabdaUah M, Brandely, Gastaut JA. Induction of cutaneous graft-versus-host hke reaction by recombinant IL-2 after autologous bone marrow transplantation. Bone Marrow Transplant 1995 16(1) 199-200. 

Massumoto C, Benyunes MC, Sale G, Beauchamp M, York A, Thompson JA, Buckner CD, Fefer A. Close simulation of acute graft-versus-host disease by interleu-kin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant 1996 17(3) 351-6. 

The safety of human M-CSF (hM-CSF) in allogeneic and syngeneic bone marrow transplantation was evaluated in a randomized, double-blind, placebo-controlled trial in 119 patients (2). There was mild transient fever in 6.7% of patients and there were no significant adverse effects on the platelet count. The incidence of graft-versus-host disease or graft rejection and the leukemic relapse rate were not affected compared with placebo. There was a similar safety profile in patients with autologous bone marrow transplants (3). 

---